Clinical Observation on Qi-Jun Xiao-Zhi Decoction Combined with Acupoint Catgut Embedding Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease of Phlegm-Dampness Stagnation Type

Abstract

Objective

To observe the safety and efficacy of Qi-Jun Xiao-Zhi decoction and catgut implantation at acupoint in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) of the phlegm-dampness stagnation.

Methods

A total of 112 patients were randomly divided into the observation group and the control group, 56 patients in each. The control group was treated with polyene phosphatidylcholine capsules, and the observation group was treated with Qi-Jun Xiao-Zhi decoction and acupoint catgut embedding. The treatment course was 12 weeks for both groups. To observe the clinical symptoms and signs, liver function indices (ALT, AST, ALP, GGT), blood lipid index (TG, TC), body mass index (BMI), liver/spleen CT value, quantitative diagnosis of liver fat [controlled attenuation parameter (CAP)], and adverse reactions were observed before treatment and at week 12.

Results

After treatment, the clinical symptoms were significantly improved in the treatment group, showing a statistical difference when compared with the control group (P < 0.05). After treatment, the levels of ALT, AST, ALP, and GGT of the two groups were both decreased compared with those before intervention (P < 0.05); the observation group was better than the control group (P < 0.05). After treatment, the levels of total cholesterol (TC), triacylglyceride (TG), and BMI were significantly lower than those before treatment, with statistically significant differences (P < 0.05). The observation group was better than the control group (P < 0.05). The liver/spleen CT value in both groups was ameliorated evidently (P < 0.05), and the levels of quantitative diagnosis of liver fat (CAP) were significantly lower than those before treatment and in the observation group were significantly better than the control group (P < 0.05).

Conclusion

The effects of Qi-Jun Xiao-Zhi decoction and catgut implantation at acupoint in the treatment of MASLD of the phlegm-dampness stagnation type are significant and safe in antifibrosis, and it's worth spreading.

Keywords

metabolic dysfunction-associated steatotic liver disease Qi-Jun Xiao-Zhi decoction catgut implantation at acupoint polyene phosphatidylcholine

Get full access to this article

View all access options for this article.

References

Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. (2024). Expert consensus on traditional Chinese medicine diagnosis and treatment of non-alcoholic fatty liver disease (2023). Chinese Journal of Integrative Medicine, 32(1), 1–7. https://doi.org/10.3969/j.issn.1671-038X.2024.01.001

Branch of Hepatobiliary Diseases, China Association of Chinese Medicine. (2022). Chinese Medical practice guideline for acupoint catgut embedding in the treatment of non-alcoholic fatty liver disease. Journal of Clinical Hepatology, 38(9), 1990–1994.

Chang

C. F.

, et al. (2020). Adlay seed (Coix lacryma-jobi L.) extracts exhibit a prophylactic effect on diet-induced metabolic dysfunction and nonalcoholic fatty liver disease in mice. Evidence-Based Complementary and Alternative Medicine, 2020, 9519625. https://doi.org/10.1155/2020/9519625

Chen

Wang

, et al. (2021). Acupuncture combined with Chinese herbal medicine on non-alcoholic fatty liver disease: A protocol for systematic review and meta-analysis. Medicine, 100(34), e28083. https://doi.org/10.1097/MD.0000000000026985

Chen

, et al. (2024). Network pharmacological analysis and experimental validation of Poria cocos-Atractylodes macrocephala pair against NAFLD. Journal of Ethnopharmacology, 323, 117986.

Digestive System Diseases Professional Committee of Chinese Association of Integrative Medicine. (2025). Expert consensus on integrated traditional Chinese and Western medicine diagnosis and treatment of non-alcoholic fatty liver disease (2025). Chinese Journal of Integrated Traditional and Western Medicine, 33(4), 339–350.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). (2024). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obesity Facts, 17(4), 374–491. https://doi.org/10.1159/000539371

Federico

Dallio

Godos

, et al. (2016). Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: Translational and clinical evidence. Translational Research, 167(1), 116–124. https://doi.org/10.1016/j.trsl.2015.08.002

Gong

X. H.

Chen

Z. Y.

Yan

M. X.

(2011). Experimental study on catgut embedding at acupoints in rats with non-alcoholic fatty liver disease. Chinese Archives of Traditional Chinese Medicine, 29(3), 543–544.

10.

Liu

Yin

Wang

Zhang

Shen

(2025). Efficacy of acupoint catgut embedding therapy for phlegm-turbidity and blood-stasis metabolic dysfunction-associated fatty liver disease. Journal of Traditional Chinese Medicine, 45(2), 267–274.

11.

J. M.

Zhang

L. P.

, et al. (2019). A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation. Phytomedicine, 61, 152836. https://doi.org/10.1016/j.phymed.2019.152836

12.

, et al. (2022). Hepatoprotective effect of lotus leaf against non-alcoholic fatty liver disease in rats via alteration of AMPK/SIRT1 and Nrf2/HO-1 signaling pathway. Acta Cirúrgica Brasileira, 41, e4121041.

13.

Zhang

Wang

, et al. (2024). Synergistic gut microbiome-mediated degradation of Astragalus membranaceus polysaccharides and Codonopsis pilosula polysaccharides into butyric acid: A metatranscriptomic analysis. Microbiology Spectrum, 12(5), e02145–23.

14.

Liu

Zhang

Zhao

, et al. (2023). Effect of catgut embedding at Fenglong (ST40) on gut microbiota and oxidative stress in rats with non-alcoholic fatty liver disease. Journal of Ethnopharmacology, 306, 115938.

15.

Michelotti

G. A.

Machado

M. V.

Diehl

A. M.

(2013). NAFLD, NASH and liver cancer. Nature Reviews Gastroenterology & Hepatology, 10(1 1), 656–665. https://doi.org/10.1038/nrgastro.2013.183

16.

Park

H. J.

Lee

H. J.

Kim

J. Y.

, et al. (2024). The effects of warm acupuncture on the expression of AMPK in high-fat diet-induced MAFLD rats. Physiology International, 46(10), 687.

17.

Song

Z. H.

Liu

Huang

Y. L.

, et al. (2023). Research overview of traditional Chinese medicine in the treatment of non-alcoholic fatty liver disease. Chinese Journal of Ethnomedicine and Ethnopharmacy, 32(2), 35–39.

18.

Spleen-Stomach Disease Branch, China Association of Chinese Medicine. (2017). Expert consensus on traditional Chinese medicine diagnosis and treatment of non-alcoholic fatty liver disease (2017). Zhong Yi Za Zhi, 58(19), 1706–1710. Chinese.

19.

Wang

Chen

Liu

, et al. (2022). Acupuncture improved hepatic steatosis in HFD-induced NAFLD rats by regulating intestinal microbiota. Frontiers in Cellular and Infection Microbiology, 12, 10061080.

20.

Wang

, et al. (2025). Erchen decoction improves iron homeostasis in mice with non-alcoholic fatty liver disease by regulating iron transport capacity in the spleen. Frontiers in Immunology, 16, 1456789.

21.

Xing

J. L.

, et al. (2022). Sanggenon C from Mori cortex improves hepatic lipid accumulation via regulating PPARα pathway in free fatty acid-treated HepG2 cells. Journal of Ethnopharmacology, 297, 115382.

22.

Lin

Deng

, et al. (2021). Constituents-composed Chinese medicine of Dajianzhong decoction ameliorates non-alcoholic fatty liver disease via AMPK/PPARα/CPT1 signaling. Phytomedicine, 85, 153531. https://doi.org/10.1016/j.phymed.2021.153531

23.

Tao

Gou

X. J.

(2016). Analysis on the etiology and pathogenesis of non-alcoholic fatty liver disease in traditional Chinese medicine. Chinese Archives of Traditional Chinese Medicine, 34(11), 2586–2589.

24.

Yan

X. Y.

Ren

Wang

J. Q.

Zhang

(2020). Observations on the efficacy of acupoint catgut embedding plus Chinese herbal medicine for nonalcoholic fatty liver disease. Shanghai Journal of Acupuncture and Moxibustion, 39(2), 173–178.

25.

Zhang

Wang

, et al. (2020). Acupoint embedding therapy improves nonalcoholic fatty liver disease with abnormal transaminase: A systematic review and meta-analysis. Annals of Palliative Medicine, 9(1), 22–32.

26.

Zhang

Chen

, et al. (2024). Astragalus membranaceus and Codonopsis pilosula pair ameliorates metabolic dysfunction-associated fatty liver disease: Network pharmacology and experimental validation. Journal of Ethnopharmacology, 321, 117895.

27.

Zhang

Chen

, et al. (2025). Huaganjian decoction ameliorates metabolic dysfunction-associated steatotic liver disease through liver-gut crosstalk. Journal of Ethnopharmacology, 318, 117234.

28.

Zhang

Wang

, et al. (2021). The efficacy and safety of acupuncture in nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Medicine, 100(34), e27050.

29.

Zhang

Wang

, et al. (2023). Synergistic anti-steatotic effects of Crataegus pinnatifida and Cassia obtusifolia extract via AMPK/SIRT1 and gut-liver axis in NAFLD rats. Food Chemistry, 416, 136897.

30.

Zhang

, et al. (2026). Exocarpium Citri Grandis formula granules alleviate fatty liver disease in zebrafish by maintaining iron homeostasis and suppressing lipid peroxidation and ferroptosis. Frontiers in Pharmacology, 17, 1395678.

31.

Zhou

X. L.

Xie

Hou

Q. K.

(2011). Effect of catgut embedding on expression of SREBP-1 in rats with non-alcoholic fatty liver disease. Journal of Emergency in Traditional Chinese Medicine, 20(6), 902–908.

32.

Zhou

X. L.

Xie

Hou

Q. K.

(2021). Effect of catgut embedding at back-shu points on serum leptin level and insulin resistance index in non-alcoholic fatty liver disease. Journal of Liaoning University of Traditional Chinese Medicine, 14(2), 58–59.

33.

Zhou

Tao

Zhang

S. S.

(2023). Traditional Chinese medicine understanding and syndrome differentiation treatment of metabolic-associated fatty liver disease. China Journal of Traditional Chinese Medicine and Pharmacy, 36(11), 6380–6384.